Pharmaceutical Technology
SEPTEMBER 15, 2022
Research by GlobalData (Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition) shows that containment facilities are in high demand as the use of cytotoxic drugs continues to grow. This adds costs and time to the processes involved.
Roots Analysis
OCTOBER 24, 2023
Owing to the advancement in clinical pharmacology and oncology domain, and the rising demand for targeted therapeutics and precision medicines, high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs have become one of the key areas of interest to researchers and drug manufacturers across the globe.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JANUARY 12, 2023
Research Associate III, who is a parenteral fill/finish and lyophilization specialist at Baxter BioPharma Solutions (BPS) – a business unit of Baxter Healthcare, Inc. Why is continuing research so important? Pharmaceutical Technology spoke with Kevin Bond Ph.D., What are the key advantages of this stabilization method?
Pharmaceutical Technology
DECEMBER 6, 2022
Manufacturing these highly potent and often cytotoxic drugs introduces many risks for operators and the environment. Cross-contamination of standard products with highly potent ones is another key concern. Many companies are now prioritising investments in containment systems, GlobalData research shows.
FDA Law Blog
JANUARY 1, 2024
The letter also stated that the company’s response to the inspection report was “inadequate because it did not include a review of environmental monitoring data in your manufacturing areas, an adequate risk analysis of previously manufactured drug product, or testing of reserve samples from impacted batches.” Dextrum Laboratories Inc.
Drug Discovery World
FEBRUARY 2, 2023
So extreme and so complex are the special safety and handling measures required during the manufacture of RRx-001 that only a handful of highly specialised contract manufacturing organisations (CMOs) in the world possess the necessary qualifications, expertise, and experience to make and store it.
The Pharma Data
MAY 4, 2021
billion, primarily driven by Pfizer CentreOne, Pfizer’s contract manufacturing operation, reflecting sales of legacy Upjohn products to Viatris (4) and remdesivir to Gilead Sciences Inc., Clinical and Research Developments. Current 2021 financial guidance is presented below. . . down 7%, which reflects relatively stable U.S.
Expert insights. Personalized for you.
130 
Let's personalize your content